How Gilead’s $1.7 Billion Deal Shapes Its Future in Inflammation January 14, 2025 Pharma & Biotech Gilead roars into JPM25 with a $1.7B deal, expanding into inflammation via STAT6 inhibitors, diversifying its portfolio, and redefining treatment landscapes. Continue Reading
